<DOC>
	<DOCNO>NCT01624051</DOCNO>
	<brief_summary>Cancer patient highly variable body composition , specifically proportion fat muscle . Some patient tend gain fat lose muscle ( lean body mass ) time . These patient develop severe muscle wasting , term sarcopenia . Patients sarcopenia severe treatment related toxicity requiring delay , dose reduction stop treatment , reduce survival . One potential explanation patient sarcopenia reduce volume lean body mass chemotherapy drug distribute , result high concentration great toxicity . This study randomize lung cancer patient either standard dosing strategy base body surface area experimental , personalize dosing base lean body mass . Based retrospective finding patient population , investigator expect find severe toxicity reduce sarcopenic patient personalize dose arm base lean body mass .</brief_summary>
	<brief_title>A Study Comparing Chemotherapy Dosing Based Either Standard Body Surface Area Lean Body Mass Patients With Advanced Lung Cancer</brief_title>
	<detailed_description>Retrospective finding NSCLC patient treat cisplatin base chemotherapy regimen show although give cisplatin standard rate 75 mg/m2 accord lean body mass , express relation individual lean body mass , high degree variation . Incidence dose limit toxicity 41 % patient whose dose within + 25 % median value . However , sarcopenic patient receive average 35 % high dose 80 % patient experience severe toxicity require dose reduction termination therapy , clinically unacceptable level . The relatively muscular subset patient higher lean body mass reduce level severe toxicity compare median dose . These finding lead design study goal reduce high level toxicity sarcopenic patient . If expect level dose limit toxicity sarcopenic patient 80 % base standard method dosing , could expect reduced median value 41 % dose limit toxicity administration cisplatin scale individual lean body mass . Hypothesis : Levels severe toxicity sarcopenic patient may reduce clinically acceptable level cisplatin dose scale 3.1 mg/kg lean body mass compare standard dose 75 mg/m2 base body surface area .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Recommendation treat oncologist receive cisplatin base chemotherapy regimen , specifically either cisplatin/vinorelbine cisplatin/gemcitabine &gt; = 18 year age Histologically proven diagnosis nonsmall cell lung cancer , Stage IIIB IV Adequate renal function : creatinine &lt; 1.5 mg/dL &lt; 132 µmol/L creatinine clearance &gt; 45 mL/min use CockcroftGault formula Adequate hepatic function : bilirubin &lt; 1.5 mg/dL &lt; 25 µmol/L AST ALT &lt; 2 time upper limit normal , unless evidence liver metastasis , case &lt; 5 time upper limit normal Adequate hematological function : absolute neutrophil count ( ANC ) &gt; 1.5 x 109/L platelet &gt; 100 x 109/L hemoglobin &gt; 100 g/L Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Negative serum pregnancy test woman childbearing potential . Women men child bear potential must use effective contraception define simultaneous use two reliable method unless abstinence choose method . Life expectancy &gt; 4 month opinion treat oncologist Prior radiotherapy allow ( unless &gt; 25 % bone marrow store ) radiation &gt; 4 week study entry patient fully recovered toxicity treatment Willingness comply study protocol Ability give write informed consent understanding may withdraw time without prejudice Pregnant lactate woman Brain metastasis ( CT MRI require rule brain metastasis unless clinical suspicion ) Previous concurrent malignancy , exclude curatively treat situ carcinoma cervix , situ ductal breast cancer , nonmelanoma skin cancer low grade bladder cancer Patients major surgery within three week enrollment without full recovery Prior treatment anticancer therapy Patients test positive HIV Any significant medical psychiatric condition , opinion investigator , exclude patient study compliance safety reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>cisplatin base chemotherapy</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>lean body mass</keyword>
	<keyword>sarcopenia</keyword>
</DOC>